top of page
News, Events and Updates
Search
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease
Nov 20, 2023
Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
Nov 6, 2023
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of
Oct 25, 2023
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Sep 14, 2023
Anavex Announces Appointment of Dr Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
Sep 12, 2023
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
Aug 8, 2023
Anavex Life Sciences Reports Publication of ANAVEX®3-71
Aug 7, 2023
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
Aug 2, 2023
Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Aug 1, 2023
Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome
Jun 28, 2023
Anavex Life Sciences and Partex Group Announce Strategic Partnership
Jun 27, 2023
3
4
5
6
7
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
